Trial Profile
TIBOHCA: A Single-centre, Phase II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After Out of Hospital Cardiac Arrest
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs 2-iminobiotin (Primary)
- Indications Asphyxia
- Focus Adverse reactions
- Acronyms TIBOHCA
- 16 Feb 2021 Status changed from recruiting to discontinued due to slow inclusion of patients.
- 23 Mar 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 23 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.